Drug Search Results
More Filters [+]

Tifacogin

Alternative Names: tifacogin
Latest Update: 2012-07-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FXa Inhibitor,TFP Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tifacogin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Pneumonia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTFP561A2308

P3

Completed

Pneumonia

2008-07-01

69%

ACTRN12607000460404

P3

Recruiting

Pneumonia

None

Recent News Events

Date

Type

Title